Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-376-140"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-376-140"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-376-1482
lpv:speaker	lp:Sophie Auconie2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 unknown; Nouveau Centre (2009-07-14--2013-05-26)3 substitute; ECON (2012-01-19--2014-06-30)3 member; Delegation to the EU-Former Yugoslav Republic of Macedonia Joint Parliamentary Committee (2009-09-16--2014-06-30)3 substitute; Delegation to the EU-Mexico Joint Parliamentary Committee (2009-09-16--2014-06-30)3 member; ENVI (2012-01-19--2014-06-30)3
lpv:translated text	"Parliament has adopted new amendments to the European legislation on pharmacovigilance to prevent the marketing of harmful medicines in the European Union. Many will recall the Mediator scandal and the legislator therefore had to intervene to ensure the safety of Europe’s citizens. By denying the Member States any room for manoeuvre, the urgent procedure will now be automatic, as the Commission wished. Moreover, the level of transparency demanded of companies has been raised greatly, requiring them to justify any voluntary withdrawal of a drug or the refusal to renew one."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph